Testing the Safety And Action of the Investigational Drug REC-4881 in People With Familial Adenomatous Polyposis (FAP) (TUPELO Study) identifier:
NCT05552755 (

Prevention study for people with an APC mutation and FAP who have had colectomy surgery

Study Contact Information:

Contact: Recursion Pharmaceuticals        
385-374-1724  or by email: [email protected]

About the Study

This study is looking at how safe and effective the research drug REC-4881 is for treating polyps in people with Familial Adenomatous Polyposis (FAP).

Participants will take the drug REC-4881 once daily by mouth. A participant's dose will depend on when they join the study. 

Participants will be followed closely for 16 weeks with bloodwork, screening and exams to look at effects of REC-4881 on the number of polyps and other changes in the polyps and to measure any side effects of the drug. 

For more information, visit the TUPELO Study page








This Study is Open To:

The study is open to adults age 55 or older who have been diagnosed with classic FAP who:

See for the full list of inclusion criteria

This Study is Not Open To:

People cannot participate who: 

See for the full list of exclusion criteria


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.